Effect of Combination of L-Arginine and L-Carnitine on Serum AGEs Level, Kidney and Endothelial Function in Patients with Chronic Heart Failure
DOI:
https://doi.org/10.6000/1929-5634.2018.07.03.2Keywords:
L-arginine, L-carnitine, kidney function, endothelial function, chronic heart failure.Abstract
The aim of the study to evaluate the effect of combination of L-Arginine with L-Carnitine on GFR, serum AGEs level and endothelial function in chronic heart failure (HF) patients with preserved ejection fraction (HFpEF).
Materials and Methods: 35 patients with mean age 60,1 [56,7; 77,3] years with an established diagnosis of HFpEF were enrolled. The patients were randomly and blindly divided into 2 groups: first (1st) group pts were treated with a combination of L-Carnitine and L-Arginine in addition to standard treatment; 2nd group pts – with L-Arginine in addition to conventional treatment. Standard laboratory blood tests, lipid profile, glucose, renal and liver function tests, serum advanced glycation end-product (AGEs) level, echocardiographic examination, flow-mediated dilatation (FMD%) were performed for all patients baseline and after 10 days of treatment. The glomerular filtration rate (GFR) was estimated using the CKD-EPI formula.
Results: Median level of AGEs was 1.72 [1.34; 1.93] mg/ml. The level of AGEs was correlated with age (R = 0.71, p<0.05), disease duration (R = 0.69, p<0.05). After 10 days of treatment with a combination of L-Carnitine with L-Arginine mean AGEs was decreased by 13.1% in comparison with L-Arginine treatment group (p=0.0003). After the treatment in 1st group mean AGEs was significantly lower in comparison with the 2nd group (p=0.004). Baseline median level of GFR was 81.2 [72,1; 86,2] ml/min and correlated with disease duration (R = 0.71, p<0.05), AGEs level (R = -0.73, p<0.05). The inclusion combination of L-arginine aspartate with L-Carnitine contributed to the significant increase of GFR level (p=0.003). The median FMD% level was 6.2 [4.4; 7.9] % and correlated with age (R=-0.61, p < 0.05), GFR (R=0.54, p < 0.05). After the 10 days it had been established significant increasing of FMD% level on 47.9 % in 1st group (p=0.0005), and on 29.3 % in 2nd group (p=0.003). Endothelial function normalizing was achieved in 10 (66 %) pts of 1st group and in 9 (45%) pts of 2nd group (p=0.002).
Conclusion: The combination of L-Carnitine, and L-Arginine improves kidney, endothelial function and contributes to decreasing of AGEs level in pts with HFpEF.
References
Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017; 14: 591-602. https://doi.org/10.1038/nrcardio.2017.65
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200. https://doi.org/10.1093/eurheartj/ehw128
Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA Guideline for the management of heart failure: a report of the American college of cardiology foundation. Circulation 2013; 128: 1810-52. https://doi.org/10.1161/CIR.0b013e31829e8807
Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation 2017; 136: 137-161. https://doi.org/10.1161/CIR.0000000000000509
Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63: 2817-27. https://doi.org/10.1016/j.jacc.2014.03.034
Lam CS, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007; 115: 1982-90. https://doi.org/10.1161/CIRCULATIONAHA.106.659763
Mohammed SF, Borlaug BA, Roger VL, et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community based study. Circ Heart Fail 2012; 5: 710-9. https://doi.org/10.1161/CIRCHEARTFAILURE.112.968594
Haykowsky MJ, Brubaker PH, Morgan TM, et al. Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass. J Gerontol A Biol Sci Med Sci 2013; 68: 968-75. https://doi.org/10.1093/gerona/glt011
Campbell RT, Jhund PS, Castagno D, et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60: 2349-56. https://doi.org/10.1016/j.jacc.2012.04.064
Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A. Impact of noncardiac comorbidities on morbidity and mortalityin a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998-1005. https://doi.org/10.1016/j.jacc.2011.11.040
Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84. https://doi.org/10.1016/j.jacc.2005.09.022
McAlister FA, Ezekowitz J, Tarantini L, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012; 5: 309-314. https://doi.org/10.1161/CIRCHEARTFAILURE.111.966242
Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J 2014; 35: 3442-3451. https://doi.org/10.1093/eurheartj/ehu254
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678. https://doi.org/10.1161/CIRCULATIONAHA.105.580506
Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35: 455-469. https://doi.org/10.1093/eurheartj/eht386
Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260 -9. https://doi.org/10.1056/NEJMoa051530
Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146. https://doi.org/10.1007/s001250051591
Raj DS, Choudhury D, Welbourne TC, et al. AGE: a nephrologist`s perspective. Am J Kidney Dis 2000; 35: 365-380. https://doi.org/10.1016/S0272-6386(00)70189-2
Kioifman B, Wollam Y, Bogomolny N, et al. Improved cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive cardiac failure. J Am Coll Cardiol 1995; 26: 1251-1256. https://doi.org/10.1016/0735-1097(95)00318-5
Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol 2014; 64: 1388-1400. https://doi.org/10.1016/j.jacc.2014.04.083
Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-Lcarnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79-91. https://doi.org/10.1196/annals.1320.007
Ponikowski P, et al. ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 2016; 37(27): 2129-200. https://doi.org/10.1093/eurheartj/ehw128
Song X, Qu H, Yang Z, Rong J, et al. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int 2017; 2017: 6274854. https://doi.org/10.1155/2017/6274854
Sciatti E, Lombardi C, Ravera A, et al. Nutritional Deficiency in Patients with Heart Failure. Nutrients 2016; 8(7): 442. https://doi.org/10.3390/nu8070442
Kuryata OV, Abdunaser A. Zabida Effect of L-Arginine on the Serum Level of Advanced Glycation End Products in Patients with Post Infarction Chronic Heart Failure. J Nutr Therapeutics 2017; 6: 43-50. https://doi.org/10.6000/1929-5634.2017.06.02.1
Tykhomyrov AA, Nedzvetsky VS, Zabida AA, Ağca CA, Kuryata OV. l-Arginine treatment improves angiogenic response and reduces matrix metalloproteinase activity in chronic heart failure patients with coronary artery disease. Pharma Nutrition 2018; 6: 137-146. https://doi.org/10.1016/j.phanu.2018.06.005
Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007; 13: 599-608. https://doi.org/10.1016/j.cardfail.2007.04.008
Damman K, Deursen VM, Navis G, Voors AA, Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582-588. https://doi.org/10.1016/j.jacc.2008.08.080
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678. https://doi.org/10.1161/CIRCULATIONAHA.105.580506
Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136(6): 137-161. https://doi.org/10.1161/CIR.0000000000000509
Anker SD, Laviano A, Filippatos G, John M, Paccagnella AP. et al. ESPEN Guidelines on parenteral nutrition: on cardiology and pneumology. Clin Nutr 2009; 28: 455-460. https://doi.org/10.1016/j.clnu.2009.04.023
Downloads
Published
How to Cite
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
